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BACKGROUND
Despite the high rate of sudden death after myocardial infarction among patients 
with a low ejection fraction, implantable cardioverter–defibrillators are contraindi-
cated until 40 to 90 days after myocardial infarction. Whether a wearable cardio-
verter–defibrillator would reduce the incidence of sudden death during this high-risk 
period is unclear.
METHODS
We randomly assigned (in a 2:1 ratio) patients with acute myocardial infarction and 
an ejection fraction of 35% or less to receive a wearable cardioverter–defibrillator plus 
guideline-directed therapy (the device group) or to receive only guideline-directed 
therapy (the control group). The primary outcome was the composite of sudden death 
or death from ventricular tachyarrhythmia at 90 days (arrhythmic death). Secondary 
outcomes included death from any cause and nonarrhythmic death.
RESULTS
Of 2302 participants, 1524 were randomly assigned to the device group and 778 to 
the control group. Participants in the device group wore the device for a median of 
18.0 hours per day (interquartile range, 3.8 to 22.7). Arrhythmic death occurred in 
1.6% of the participants in the device group and in 2.4% of those in the control group 
(relative risk, 0.67; 95% confidence interval [CI], 0.37 to 1.21; P = 0.18). Death from 
any cause occurred in 3.1% of the participants in the device group and in 4.9% of 
those in the control group (relative risk, 0.64; 95% CI, 0.43 to 0.98; uncorrected 
P = 0.04), and nonarrhythmic death in 1.4% and 2.2%, respectively (relative risk, 0.63; 
95% CI, 0.33 to 1.19; uncorrected P = 0.15). Of the 48 participants in the device group 
who died, 12 were wearing the device at the time of death. A total of 20 participants 
in the device group (1.3%) received an appropriate shock, and 9 (0.6%) received an 
inappropriate shock.
CONCLUSIONS
Among patients with a recent myocardial infarction and an ejection fraction of 35% 
or less, the wearable cardioverter–defibrillator did not lead to a significantly lower 
rate of the primary outcome of arrhythmic death than control. (Funded by the National 
Institutes of Health and Zoll Medical; VEST ClinicalTrials.gov number, NCT01446965.)
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The incidence of sudden cardiac death is high during the early months after a myocardial infarction,1-3 particu-
larly among patients with a low left ventricular 
ejection fraction.2-7 Implantable cardioverter–
defibrillators (ICDs) reduce mortality among 
patients with a reduced ejection fraction when 
the devices are implanted months to years after 
myocardial infarction.8-10 However, two random-
ized trials did not show a long-term mortality 
benefit from ICDs that had been implanted im-
mediately after myocardial infarction.11,12
The wearable cardioverter–defibrillator may 
protect against sudden death during the imme-
diate period after myocardial infarction, before 
ICD implantation is indicated under current 
guidelines (beginning 40 days after myocardial 
infarction or 90 days if the patient has under-
gone revascularization).13,14 Registries and case 
series involving high-risk patients have shown 
that wearable cardioverter–defibrillators are ef-
fective in terminating ventricular tachyarrhyth-
mias.15-19 We conducted the Vest Prevention of 
Early Sudden Death Trial (VEST) — a multi-
center, randomized, controlled trial — to deter-
mine the efficacy of a wearable cardioverter–
defibrillator during the period before ICDs are 
indicated in patients who have had a myocardial 
infarction and have a reduced ejection fraction.
Me thods
Trial Design and Oversight
The trial protocol (available with the full text of 
this article at NEJM.org) was designed by the 
investigators and originally included two com-
ponents: the VEST randomized trial and the 
observational Prediction of ICD Treatment Study 
(PREDICTS)20; only the results of VEST are re-
ported in this article. The protocol was approved 
by the institutional review boards of the Univer-
sity of California, San Francisco, and the other 
trial sites. Details of the history of the trial, the 
role of the sponsors, and the trial oversight are 
provided in Figure S1 and Tables S1, S2, and S3 
in the Supplementary Appendix (available at 
NEJM.org).
The trial was initially funded by the National 
Institutes of Health, which appointed the mem-
bers of the independent data and safety monitor-
ing board, with additional support from Zoll 
Medical. After 2011, funding was provided exclu-
sively by Zoll Medical. Zoll Medical had no role 
in the trial design, the selection or supervision 
of trial centers, the analysis or interpretation of 
the data, the preparation of the manuscript, or the 
decision to submit the manuscript for publica-
tion. Zoll Medical did participate in site moni-
toring. The authors vouch for the completeness 
and accuracy of the data and for the fidelity of 
the trial to the protocol.
Participants
Patients who had been hospitalized with an acute 
myocardial infarction21 and who had an ejection 
fraction of 35% or less (assessed ≥8 hours after 
myocardial infarction) were enrolled within 7 days 
after hospital discharge. For patients who had 
undergone revascularization, the ejection fraction 
was assessed 8 or more hours after percutaneous 
coronary intervention (PCI) or 48 or more hours 
after coronary-artery bypass grafting. Patients 
were excluded if they had an ICD or unipolar 
pacemaker, had clinically significant valve dis-
ease, were undergoing long-term hemodialysis, or 
had a chest circumference that was too small 
or too large to accommodate the wearable cardio-
verter–defibrillator. Patients were also excluded 
if they were pregnant or had been discharged to 
a nursing facility with an anticipated stay of more 
than 7 days. The inclusion and exclusion criteria 
are provided in Table S4 in the Supplementary 
Appendix. All the participants provided written 
informed consent.
Trial Procedures
Eligible participants were randomly assigned in a 
2:1 ratio to receive a wearable cardioverter–defi-
brillator plus guideline-directed medical therapy 
(the device group)22-27 or to receive guideline-
directed medical therapy alone (the control group) 
at hospital discharge. The Zoll LifeVest wearable 
cardioverter–defibrillator16-18,28,29 that was used in 
this trial was commercially available in the United 
States and Germany (Fig. S2 in the Supplemen-
tary Appendix). Participants in the device group 
were fitted with the device, trained in its use, 
and instructed to wear the device continuously 
for 3 months (except while bathing). Sites were 
alerted if a participant wore the device for less 
than 15 hours in a 24-hour period (monitored 
through the device itself). Arrhythmias that were 
detected by the device were not reported to treat-
ing physicians or the trial sites unless a shock 
A Quick Take 
is available at 
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was delivered or cardiac arrest occurred. Per 
protocol, crossovers from the control group to 
the wearable cardioverter–defibrillator were not 
allowed, and early ICD implantation (<3 months) 
was allowed only for guideline-based secondary 
prevention of sudden death.14,30,31
Follow-up and Outcomes
Participants were followed at 1 month with a 
telephone call and at 3 months with an in-person 
visit. At the conclusion of the trial, the National 
Death Index was searched for U.S. participants 
for whom vital status was unknown.
Initially, the primary outcome of the trial was 
death from any cause at 60 days; however, slower-
than-expected recruitment made the originally 
planned sample of 4506 patients infeasible. On 
January 29, 2010, after the first 244 participants 
had been enrolled, the data and safety monitor-
ing board, the steering committee, and the insti-
tutional review boards approved a change in the 
primary outcome to the combined 90-day inci-
dence of sudden death and nonsudden death due 
to ventricular tachyarrhythmia; we refer to this 
outcome as arrhythmic death. The cause of death 
was adjudicated by an independent panel of ex-
perts who were unaware of the group assign-
ments (and therefore did not have any data from 
the wearable cardioverter–defibrillator). With the 
revised primary outcome, the sample-size target 
was changed to 1890 (see the Supplementary 
Appendix). In October 2015, on the basis of 
lower-than-expected device wear time and with-
out the inspection of outcome differences ac-
cording to trial group32,33 (as prespecified in the 
protocol), the data and safety monitoring board 
recommended increasing the sample to 2300 
patients.
Secondary outcomes were death from any 
cause; nonarrhythmic death; hospitalization for 
myocardial infarction, atrial fibrillation, conges-
tive heart failure, stroke, or sustained ventricular 
tachyarrhythmia; wearable cardioverter–defibril-
lator wear time (as monitored by the device); and 
adverse events (Table S5 in the Supplementary 
Appendix). Definitions for the adjudicated out-
comes are provided in the Supplementary Ap-
pendix.
Statistical Analysis
The primary analysis was performed according 
to the intention-to-treat principle. In the primary 
analysis, participants who had an indeterminate 
cause of death were assumed not to have had 
arrhythmic death but were counted in the out-
come of death from any cause, and all the par-
ticipants with missing vital status were assumed 
to be alive. The primary outcome as well as 
death from any cause, nonarrhythmic death, and 
rehospitalization were compared with the use of 
unadjusted log-binomial models (with relative 
risks reported), with P values assessed by Pearson 
chi-square tests. Time-to-event analyses were 
conducted with the use of Cox models and are 
reported as Kaplan–Meier plots with hazard ra-
tios. Rare events (indeterminate cause of death 
and other clinically significant arrhythmias — 
nonatrial fibrillation and nonventricular tachy-
arrhythmias) were analyzed with the use of exact 
logistic regression. The risk of having an alarm 
indicating arrhythmia was estimated with the 
use of random-effects logistic models to account 
for within-person clustering. P values are reported 
without correction for multiple comparisons, ex-
cept where noted. Additional analyses, including 
sensitivity analyses to account for missing data, 
survival analyses (performed with the Kaplan–
Meier method), P value corrections for multiple 
comparisons, and as-treated analyses are de-
scribed in the Supplementary Appendix.
R esult s
Characteristics of the Participants
From July 2008 through April 2017, we enrolled 
2348 participants at 76 sites in the United States, 
at 24 in Poland, at 6 in Germany, and at 2 in 
Hungary (Table S6 in the Supplementary Appen-
dix). One U.S. site was dismissed on June 24, 
2014, and the 46 participants at that site were 
excluded from the analyses, owing to irregulari-
ties found by the institutional review board at 
that site.
Therefore, a total of 2302 participants were 
included in the analyses (1524 participants in 
the device group and 778 in the control group) 
(Fig. S3 in the Supplementary Appendix). The two 
groups were balanced with regard to the par-
ticipants’ demographic characteristics, medical 
history, and characteristics of the index hospital-
ization for myocardial infarction (Table 1). The 
mean ejection fraction was 28%, and 83.6% of 
the participants underwent PCI during the index 
hospitalization. Table S7 in the Supplementary 
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Characteristic
Device Group 
(N = 1524)
Control Group 
(N = 778)
Age — yr 60.9±12.6 61.4±12.3
Male sex — no./total no. (%) 1108/1521 (72.8) 577/772 (74.7)
Body-mass index† 28.4±5.5 28.4±5.5
Race or ethnic group — no./total no. (%)‡
White 1279/1491 (85.8) 636/751 (84.7)
Black 143/1491 (9.6) 75/751 (10.0)
Asian 23/1491 (1.5) 14/751 (1.9)
Native American or Alaskan 25/1491 (1.7) 12/751 (1.6)
Pacific Islander or Hawaiian 1/1491 (0.1) 0/751
Multiple 20/1491 (1.3) 14/751 (1.9)
Hispanic 85/1521 (5.6) 34/772 (4.4)
Baseline condition before index hospitalization — no./total no. (%)
Current smoking 561/1520 (36.9) 273/770 (35.5)
Diabetes mellitus 497/1521 (32.7) 246/776 (31.7)
Hypertension 994/1521 (65.4) 501/776 (64.6)
Previous myocardial infarction 380/1518 (25.0) 193/775 (24.9)
Previous CABG 133/1521 (8.7) 70/776 (9.0)
Previous PCI 374/1520 (24.6) 202/776 (26.0)
Previous congestive heart failure 247/1518 (16.3) 146/774 (18.9)
NYHA functional class
I 691/1520 (45.5) 326/775 (42.1)
II 529/1520 (34.8) 286/775 (36.9)
III 211/1520 (13.9) 116/775 (15.0)
IV 46/1520 (3.0) 18/775 (2.3)
Index hospitalization for myocardial infarction
Left ventricular ejection fraction§
Mean 28.2±6.1 28.2±5.8
Distribution — no./total no. (%)
<25% 301/1519 (19.8) 148/777 (19.0)
25 to 35% 1217/1519 (80.1) 627/777 (80.7)
>35% 1/1519 (0.1) 2/777 (0.3)
PCI during index hospitalization — no./total no. (%) 1275/1513 (84.3) 650/773 (84.1)
Thrombolytic agent during index hospitalization —  
no./total no. (%)
118/1513 (7.8) 71/773 (9.2)
CABG during index hospitalization — no. (%) 14 (0.9) 12 (1.5)
Cardiac arrest or ventricular fibrillation — no./total no. (%) 169/1513 (11.2) 70/773 (9.1)
Pulmonary edema leading to intubation — no./total no. (%) 162/1513 (10.7) 88/773 (11.4)
Intraaortic balloon pump — no./total no. (%) 173/1513 (11.4) 93/773 (12.0)
Cardiogenic shock — no./total no. (%) 136/1513 (9.0) 79/773 (10.2)
Atrial fibrillation during hospitalization — no./total no. (%) 156/1513 (10.3) 91/773 (11.8)
Median maximum creatinine level (IQR) — mg/dl¶ 1.1 (0.9–1.3) 1.1 (0.9–1.4)
Median no. of days from admission to randomization (IQR) 5.0 (3.0–8.0) 5.0 (3.0–7.0)
*  Plus–minus values are means ±SD. There were no significant differences (P<0.05) between the trial groups. Percent-
ages may not total 100 because of rounding. CABG denotes coronary-artery bypass grafting, IQR interquartile range, 
NYHA New York Heart Association, and PCI percutaneous coronary intervention.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race and ethnic group were reported by the participant.
§  An ejection fraction of 35% or less was an inclusion criterion for the study. An ejection fraction of more than 35% 
 represents a protocol violation.
¶  To convert values for creatinine to micromoles per liter, multiply by 88.4.
Table 1. Characteristics of the Participants.*
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on October 14, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;13 nejm.org September 27, 2018 1209
Wear able Cardioverter–Defibrillator after MI
Appendix shows the baseline characteristics of 
the participants who were enrolled before versus 
after the protocol was amended to change the 
primary outcome.
Intervention and Treatment
The majority of the participants in each group 
received guideline-directed medical therapy for 
myocardial infarction and heart failure (Table 2). 
In the device group, 43 participants (2.8%) never 
wore the device after randomization; in the con-
trol group, 20 participants (2.6%) received the 
device outside the protocol. Including person-days 
in which the wearable cardioverter–defibrillator 
was not worn at all, participants in the device 
group wore the device for a median of 18.0 hours 
per day (interquartile range, 3.8 to 22.7) and for 
a mean (±SD) of 14.0±9.3 hours per day (Table 2), 
with decreasing use over time. Details are pro-
vided in Figures S3 and S4 in the Supplementary 
Appendix. There was no significant between-
group difference in the rate of ICD implantation 
during the follow-up period, nor was there a sig-
nificant between-group difference in the timing 
of or reason for implantation (Table 2, and Table 
S8 in the Supplementary Appendix).
Follow-up and Outcomes
The mean follow-up was 84.3±15.6 days. A total 
of 10 participants (0.7%) in the device group and 
Treatment
Device Group 
(N = 1524)
Control Group 
(N = 778) P Value
Wearable cardioverter–defibrillator
Patients with device — no. (%)† 1481 (97.2) 20 (2.6) <0.001
Hours per day that device was worn during follow-up‡
Median (IQR) 18.0 (3.8–22.7) 0.0 (0.0–0.0) <0.001
Mean 14.0±9.3 0.4±2.7 <0.001
Implantable cardioverter–defibrillator
Patients with device — no. (%)§ 67 (4.4) 44 (5.7) 0.18
Median no. of days from randomization to implantation 
(IQR)
62 (24–81) 58 (25–77) 0.33
Medication use — no. (%)¶
Aspirin 1329 (87.2) 678 (87.1) 0.97
Other antiplatelet agent 1379 (90.5) 680 (87.4) 0.02
Statin 1386 (90.9) 696 (89.5) 0.25
Beta-blocker, including carvedilol 1411 (92.6) 720 (92.5) 0.97
ACE inhibitor or ARB 1334 (87.5) 667 (85.7) 0.23
Eplerenone or spironolactone 662 (43.4) 343 (44.1) 0.77
Other diuretic agent 736 (48.3) 385 (49.5) 0.59
Amiodarone 106 (7.0) 55 (7.1) 0.92
Other antiarrhythmic agent of class IA, IC, or III 5 (0.3) 4 (0.5) 0.50
Digoxin 86 (5.6) 44 (5.7) 0.99
*  P values were not corrected for multiple comparisons. ACE denotes angiotensin-converting enzyme, and ARB angio-
tensin-receptor blocker .
†  The use of any wearable cardioverter–defibrillator by participants in the control group was a protocol violation.
‡  The number of hours per day that the wearable cardioverter–defibrillator was worn included follow-up days after dis-
charge from the hospital and before death or implantable cardioverter–defibrillator (ICD) implantation and also includ-
ed participants who did not wear it at all (0 hours per day on those days) in the two groups in order to describe the dif-
ference in the device coverage according to group. A total of 11 participants (4 in the device group and 7 in the control 
group) who died before discharge from the hospital were excluded from this analysis.
§  The implantation of an ICD in a participant in either group before 90 days of follow-up, unless for acceptable clinical 
 indications for secondary prevention (e.g., cardiac arrest or sustained ventricular tachycardia during follow-up), was a 
protocol violation (Table S6 in the Supplementary Appendix).
¶  Participants provided details regarding medication use at follow-up visits.
Table 2. Treatment Received during the Trial Period.*
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12 (1.5%) in the control group were lost to fol-
low-up, and their vital status at 90 days was 
unknown. An additional 2 participants in each 
group had insufficient data to determine wheth-
er the cause of death was arrhythmic or nonar-
rhythmic; therefore, they were considered to 
have had an indeterminate cause of death.
There was no significant difference between 
the two groups in the primary outcome of ar-
rhythmic death (1.6% in the device group and 
2.4% in the control group; relative risk, 0.67; 
95% confidence interval [CI], 0.37 to 1.21; 
P = 0.18) (Table 3 and Fig. 1). The total mortality 
was 3.1% in the device group, as compared with 
4.9% in the control group (relative risk, 0.64; 
95% CI, 0.43 to 0.98; uncorrected P = 0.04). The 
rate of nonarrhythmic death was 1.4% in the 
device group and 2.2% in the control group 
Event
Device Group 
(N = 1524)
Control Group 
(N = 778)
Relative Risk 
(95% CI) P Value
Arrhythmic death
No. of patients (%)† 25 (1.6) 19 (2.4) 0.67 (0.37–1.21) 0.18
Device worn at time of death or event leading to death — no. 9 0 NA
Nonarrhythmic death
No. of patients (%)‡ 21 (1.4) 17 (2.2) 0.63 (0.33–1.19) 0.15
Device worn at time of death or event leading to death — no. 2 0 NA
Indeterminate death
No. of patients (%)§ 2 (0.1) 2 (0.3) 0.51 (0.04–7.05) 0.83
Device worn at time of death or event leading to death — no. 1 0 NA
Death from any cause
No. of patients (%) 48 (3.1) 38 (4.9) 0.64 (0.43–0.98) 0.04
Device worn at time of death or event leading to death — no. 12 0 NA
Rehospitalization, by cause — no. (%)¶
Any 475 (31.2) 253 (32.5) 0.96 (0.85–1.09) 0.51
Cardiovascular or trial-related cause 335 (22.0) 174 (22.4) 0.98 (0.84–1.16) 0.83
Recurrent myocardial infarction 53 (3.5) 32 (4.1) 0.85 (0.55–1.30) 0.44
Stroke 14 (0.9) 8 (1.0) 0.89 (0.38–2.12) 0.80
Congestive heart failure 87 (5.7) 52 (6.7) 0.85 (0.61–1.19) 0.35
Ventricular tachycardia or ventricular fibrillation 24 (1.6) 20 (2.6) 0.61 (0.34–1.10) 0.10
Atrial fibrillation 8 (0.5) 5 (0.6) 0.82 (0.27–2.49) 0.72
Other clinically significant arrhythmia 8 (0.5) 3 (0.4) 1.36 (0.33–8.00) 0.92
*  For common outcomes (including for the primary outcome of arrhythmic death and for other outcomes with at least five events in each 
group), a simple Pearson chi-square test was used to obtain P values, and log-binomial regression was used to estimate a relative risk with 
confidence intervals. For rare outcomes (<5 events in one or both groups), P values and relative risks were estimated with the use of exact 
logistic regression under the assumption that odds ratios produced by logistic regression are good estimates of relative risk when the out-
come is rare. P values were not corrected for multiple comparisons. Details regarding the deaths or events leading to death that occurred 
while the participant was wearing the device are provided in Table S12 in the Supplementary Appendix. NA denotes not applicable.
†  The primary outcome of arrhythmic death included sudden death and nonsudden death due to ventricular tachyarrhythmia.
‡  Nonarrhythmic death included all the deaths that did not meet the criteria for either arrhythmic death or indeterminate death (see below).
§  When documentation was inadequate for characterization of deaths as arrhythmic or nonarrhythmic, they were categorized as being indeter-
minate. Details are provided in the Supplementary Appendix.
¶  Site investigators were instructed to report all the hospitalization events occurring during follow-up if they were for conditions related to the 
heart or major arteries or to a trial procedure. These events were adjudicated for the presence of myocardial infarction, stroke, congestive heart 
failure, ventricular tachycardia or ventricular fibrillation, and other clinically significant arrhythmia with the use of standard criteria (see the 
Supplementary Appendix). Investigators were also asked to report the number of hospitalization events for any cause; these events were not 
adjudicated.
Table 3. Primary, Secondary, and Other Outcomes.*
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(relative risk, 0.63; 95% CI, 0.33 to 1.19; uncor-
rected P = 0.15). With most approaches to correc-
tion for multiple testing, the P value for the 
analysis of total mortality was not significant 
(Table S9 in the Supplementary Appendix).
Results from the prespecified weighted sensi-
tivity analyses to account for participants with 
unknown vital status or an indeterminate cause 
of death were similar to those of the primary 
analyses (Table S10 in the Supplementary Ap-
pendix). Analyses that were adjusted for the dif-
ferences in length of follow-up owing to proto-
col changes were also similar to the main 
outcome analyses (Table S11 in the Supplemen-
tary Appendix). We found no significant be-
tween-group differences in the rates of other 
secondary events (Table 3).
Among the 48 participants in the device 
group who died, 12 were wearing the device at 
the time of death, including 9 of the 25 partici-
pants who had arrhythmic death (Table S12 in 
the Supplementary Appendix). Of these 9 par-
ticipants, 4 had had a ventricular tachyarrhyth-
mia detected and had received appropriate 
shocks with conversion to sinus rhythm but with 
subsequent recurrent ventricular tachyarrhyth-
mias or agonal rhythms. In the remaining par-
ticipants, no tachyarrhythmias were recorded. 
One other participant received an appropriate 
shock and underwent ICD implantation but died 
2 weeks later with ventricular tachyarrhythmia 
storm. A total of 6 participants who died while 
wearing the device had asystole events (>3-sec-
ond pause) during death (in 2 participants, these 
were preceded by multiple ventricular tachyar-
rhythmia episodes and shocks), which may rep-
resent terminal rhythms.
An as-treated analysis showed a rate of ar-
rhythmic death of 0.37 per 100 person-months 
of wearing the device, as compared with a rate 
of 0.86 per 100 person-months of not wearing 
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Figure 1. Time-to-Event Curves for the Primary 
 Outcome and Two Secondary Outcomes.
The primary outcome was a composite of sudden 
death or death due to ventricular tachyarrhythmia 
(Panel A). Secondary outcomes included nonarrhythmic 
death (Panel B) and death from any cause (Panel C).  
P values were not corrected for multiple comparisons. 
Insets show the same data on an enlarged y axis.
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the device (rate ratio, 0.43; 95% CI, 0.21 to 0.91; 
uncorrected P = 0.03) (see the Supplementary Ap-
pendix). An as-treated analysis of total mortality 
showed a rate of 0.50 per 100 person-months of 
wearing the device, as compared with a rate of 
1.91 per 100 person-months of not wearing the 
device (rate ratio, 0.26; 95% CI, 0.14 to 0.48; 
Bonferroni corrected P<0.001). Adjustment for 
age, education, ejection fraction, and revascular-
ization had minimal effects. Potential biases in 
the as-treated analyses are discussed in the 
Supplementary Appendix.
Safety and Adverse Events
During a total of 1,765,772 hours of wearable 
cardioverter–defibrillator wear time, participants 
received 57,451 alarms for possible arrhythmias 
(as determined by the device algorithms); the 
Variable Device Group (N = 1524) Control Group (N = 778) P Value
no. of participants with event (%)
No. of total shocks <0.001
0 1495 (98.1) 777 (99.9)
1 20 (1.3) 0
≥2 9 (0.6) 1 (0.1)
No. of appropriate shocks 0.008
0 1504 (98.7) 777 (99.9)
1 13 (0.9) 0
≥2 7 (0.5) 1 (0.1)
No. of inappropriate shocks 0.12
0 1515 (99.4) 778 (100)
1 7 (0.5) 0
≥2 2 (0.1) 0
No. of shocks aborted by pressing response 
button†
<0.001
0 1455 (95.5) 777 (99.9)
1 43 (2.8) 1 (0.1)
2–5 11 (0.7) 0
>5 15 (1.0) 0
No. of alarms indicating arrhythmia <0.001
0 432 (28.3) 762 (97.9)
1 115 (7.5) 1 (0.1)
2–5 252 (16.5) 2 (0.3)
6–100 579 (38.0) 12 (1.5)
>100 146 (9.6) 1 (0.1)
No. of alarms indicating asystole <0.001
0 1483 (97.3) 777 (99.9)
1 22 (1.4)‡ 0
≥2 19 (1.2)‡ 1 (0.1)
*  Shown are the numbers of participants who had an event over the entire 90-day period. The wearable cardioverter– 
defibrillator was used by 20 participants in the control group, who received the device outside the protocol. Percentages 
may not total 100 because of rounding. P values were not corrected for multiple comparisons.
†  This analysis included arrhythmia alarms lasting more than 30 seconds that were aborted when the participant pressed 
the shock-suppression button.
‡  Among 41 participants with an alarm indicating asystole, 6 events (all in the device group) were adjudicated as having 
had a true asystole event.
Table 4. Wearable Cardioverter–Defibrillator Therapies and Alarms.*
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average rate (number of alarms ÷ total wear time 
in hours) was 0.033 alarms per hour. With adjust-
ment for clustering of alarms according to day 
and within participant, the chance that a partici-
pant would have at least 1 arrhythmia alarm 
during 24 hours of wear time was 10.8% (95% 
CI, 9.8 to 11.9). Overall, accounting for crossovers 
and variable time worn, arrhythmia alarms (both 
false and true detections) occurred in 72% of the 
participants in the device group and in 2% of 
those in the control group, with 9.6% of partici-
pants in the device group being exposed to more 
than 100 alarms over the 90-day period (Table 4). 
The median duration of the arrhythmia alarm 
was 7 seconds (interquartile range, 3 to 12).
A total of 29 participants in the device group 
received at least one shock from the wearable 
cardioverter–defibrillator (Table 4); 20 participants 
(1.3%) received at least one appropriate shock, 
and 9 (0.6%) received at least one inappropriate 
shock. Of the 21 participants who received an ap-
propriate shock (20 in the device group and 1 in 
the control group), 6 died (all in the device group). 
A total of 69 participants in the device group 
aborted shocks by pressing the patient-response 
buttons during an alarm; 3 of these participants 
subsequently received appropriate shocks within 
a few minutes but died, and 1 other participant 
died 12 hours later, after an appropriate shock 
(Table S12 in the Supplementary Appendix).
Four adverse events were potentially related to 
the wearable cardioverter–defibrillator (Table S13 
in the Supplementary Appendix). Three were 
hospitalizations (two for aborted shocks and one 
for an inappropriate shock), and one was a death 
while the participant was wearing the device, 
which was deemed likely to not be an arrhythmic 
death (no tachyarrhythmia was recorded by the 
device and emergency medical technicians noted 
pulseless electrical activity on arrival).
A higher proportion of participants in the de-
vice group than in the control group reported itch 
and rash (P<0.001). A lower proportion of par-
ticipants in the device group than in the control 
group reported shortness of breath (P = 0.004). 
Details are provided in Table S14 in the Supple-
mentary Appendix.
Discussion
VEST compared the use of a wearable cardio-
verter–defibrillator plus guideline-directed med-
ical therapy with guideline-directed medical ther-
apy alone in patients who presented with an acute 
myocardial infarction with an ejection fraction 
of 35% or less. During follow-up, we observed 
cardiac event rates that were similar to those in 
previous studies.3,4,6,11,12 The wearable cardio-
verter–defibrillator did not lead to a rate of ar-
rhythmic death during the first 90 days — the 
primary outcome of the trial — that was sig-
nificantly lower than the rate with guideline-
directed medical therapy alone.
The trial may have been underpowered to 
detect a beneficial effect of the wearable cardio-
verter–defibrillator on the primary outcome. Our 
power calculation anticipated a 58% lower rate 
of arrhythmic death with the device than with-
out it. The power was, in part, reduced because 
5% of the deaths were adjudicated as being of 
indeterminate cause and were thus removed from 
the primary analysis. Misclassification of the 
adjudicated cause of death may have further re-
duced the power for the primary outcome. It is 
difficult to determine an arrhythmic cause of 
death accurately for unwitnessed deaths or deaths 
with limited documentation. In the Valsartan in 
Acute Myocardial Infarction (VALIANT) trial, 
only half the patients with sudden death who 
underwent autopsy were found to have died from 
arrhythmic death.34 In a recent study that used a 
definition of sudden death that was similar to 
the definition in our trial but that also used 
autopsy as a standard for determining cause of 
death, only 56% of the presumed sudden cardiac 
deaths were found to be of arrhythmic origin.35 
In our trial, five of nine participants with adju-
dicated arrhythmic death who were wearing the 
device during the event had no ventricular tachy-
arrhythmias (adjudicators were unaware of the 
arrhythmia data from the device).
The original primary outcome of the trial was 
death from any cause; for this outcome, the un-
corrected P value for comparison was 0.04 in 
favor of the wearable cardioverter–defibrillator. 
However, this result was not corrected for mul-
tiple testing, and given the use of most such 
corrections, the difference between the device 
and control groups would not be significant. 
Thus, the conservative interpretation is that this 
result was a chance finding. As with the pri-
mary outcome, the trial may have been under-
powered to detect a beneficial effect of the de-
vice with regard to all-cause mortality. Although 
there is no clear mechanism to explain a benefit 
of the wearable cardioverter–defibrillator on non-
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arrhythmic death, it is often difficult to deter-
mine an arrhythmic cause of death, as noted 
above.
As described previously,15-17 the wearable cardio-
verter–defibrillator was effective at converting 
ventricular tachyarrhythmias, with successful 
conversion in all 20 participants in the device 
group who received an appropriate shock, 14 of 
whom survived to 90 days (Table S12 in the 
Supplementary Appendix). Nonadherence to wear-
ing the device may have reduced the power of 
the trial to show the effectiveness of this treat-
ment strategy for the prevention of arrhythmic 
death. The power calculation assumed a device-
adherence rate of 70%, a goal that was met or 
exceeded in the first 2 weeks after randomiza-
tion but that waned over time (Fig. S4 in the 
Supplementary Appendix). It is also evident that 
some patients who are successfully treated with 
an appropriate shock subsequently die; not all 
successful defibrillations prolong survival. How-
ever, in an as-treated analysis, a significantly 
lower percentage of patients died when they 
were wearing the wearable cardioverter–defibril-
lator than when they were not, a finding that 
remained significant even after the most conser-
vative correction for multiple comparisons. Al-
though this result is subject to bias, it suggests 
a benefit to wearing the device (see the Supple-
mentary Appendix) and implies that low adher-
ence to wearing the device may be a limiting 
factor in the potential benefit of the wearable 
cardioverter–defibrillator.
Guidelines for primary prevention of sudden 
death with ICD implantation recommend wait-
ing 40 days after an acute myocardial infarction 
and 90 days after revascularization. Randomized 
trials have shown no benefit to ICD implanta-
tion early after an acute myocardial infarction.11,12 
However, mortality was high during this vulner-
able period, even with guideline-directed medi-
cal therapy and revascularization. We observed 
that mortality at 90 days was 4.9% in the control 
group, despite 84% of the participants having 
undergone PCI for acute myocardial infarction 
and more than 85% being treated with guide-
line-directed medical therapy. It remains unclear 
how to reduce the risk of arrhythmic death de-
finitively, beyond what is possible with appropri-
ate medical therapy, in the early period after 
myocardial infarction before ICDs are indicated.
In conclusion, in this trial, we compared the 
use of a wearable cardioverter–defibrillator plus 
guideline-directed medical therapy with guide-
line-directed medical therapy alone in patients 
who presented with an acute myocardial infarc-
tion with an ejection fraction of 35% or less. The 
wearable cardioverter–defibrillator did not result 
in a significantly lower rate of arrhythmic death 
than medical therapy during the first 90 days.
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